Merus to Participate in William Blair's Biotech Focus Conference 2021
The live webcast of the panel discussion will be available on the Investors page of the Company's website. An archived presentation will be available on the Merus website for a limited time.
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and twitter.
Investor and Media Inquiries:
Kathleen FarrenMerus N.V. Communications Specialist 617-230-4165 firstname.lastname@example.org